Giancarlo Colombo
Gian Luigi Gessa- Neuroscience Institute, Section of Cagliari, National Research Council of Italy, Monserrato, Italy
This paper summarizes the several lines of experimental evidence demonstrating the ability of the prototypic GABAB receptor agonist, baclofen, to suppress multiple alcohol-related behaviors in laboratory rodents and non-human primates exposed to validated experimental models of alcohol use disorder (AUD). Specifically, treatment with baclofen has repeatedly been reported to suppress alcohol-induced locomotor stimulation, alcohol drinking (including binge- and relapse-like drinking), operant oral alcohol self-administration, alcohol seeking, and reinstatement of alcohol seeking in rats and mice. Treatment with baclofen also reduced operant oral alcohol self-administration in baboons. Several of these effects appear to be mediated by GABAB receptors located in the ventral tegmental area. The often observed co-occurrence of “desired” pharmacological effects and “unwanted” sedative effects represents the major drawback of the preclinical, anti-alcohol profile of baclofen. Collectively, these data underline the role of the GABAB receptor in the mediation of several alcohol-related behaviors. These data possess remarkable translational value, as most of the above effects of baclofen have ultimately been reproduced in AUD patients.
Baclofen Effect on Alcohol-Induced Stimulation of Locomotor Activity
Historically, the first study investigating the effect of the GABAB receptor orthosteric agonist, baclofen, on an alcohol-induced response in vivo was conducted in Sweden more than 40 years ago (1); it included, amongst the authors, the Nobel laureate Arvid Carlsson. This study found that acute pretreatment with 5 mg/kg baclofen (i.p.) completely abolished alcohol-stimulated locomotor activity in mice. Besides being the “foundation stone” in the alcohol-baclofen research field, this study was of relevance for the translational value of its data: drug-induced hyperlocomotion in rodents and euphoria in humans are indeed homologous phenomena, as they are mediated by common neural systems [see (2)]; accordingly, in their paper Carlsson and his colleagues wrote that their finding “may be of heuristic value in the treatment of chronic alcoholism,”, hypothesizing the translation of the ability of baclofen to suppress alcohol-stimulated locomotor activity in mice to alcohol stimulating and euphorigenic effects in humans.
These initial results have been confirmed by a series of subsequent studies reporting the suppressing effect of acutely administered baclofen on alcohol-stimulated locomotor activity in alcohol-preferring “University of Chile bibulous” (UChB) rats (3) and mice belonging to different strains and lines (4–9). Baclofen-induced suppression of alcohol-stimulated locomotor activity has also been recorded in preweanling (12-day-old) Sprague-Dawley rats (10), suggesting the involvement of the GABAB receptor system in the mediation of the stimulating effects of alcohol already in this developmental period.
Baclofen Effect on Alcohol Drinking
Homecage Alcohol Drinking
Human alcohol drinking is conventionally modeled in rodents by exposing rats and mice—usually singly housed in their homecage—to the choice between a water bottle and a bottle containing an alcohol solution. Under this simple procedure, animals can freely choose when and how much alcohol they drink. Under specific experimental conditions, this regimen results in voluntary intakes of psychopharmacologically relevant amounts of alcohol, mimicking excessive alcohol drinking (too much, too often) in humans and providing a reliable tool for pharmacological tests [see (11)].
Several studies have used the 2-bottle “alcohol vs. water” choice regimen to investigate baclofen effect on alcohol drinking. In most studies, acute or repeated systemic administration of baclofen produced substantial reductions in alcohol intake [(3, 12–16); see however (17)] in alcohol-experienced rats and mice. “Alcohol-experienced” means that, in these animals, consumption of high doses of alcohol was already consolidated before the start of treatment with baclofen; these animals are thought to model the “maintenance” or “active drinking” phase of human alcohol use disorder (AUD). Repeated i.p. treatment with 2.5 and 5 mg/kg racemic baclofen or the corresponding doses of R(+)-baclofen (the active enantioner) markedly reduced daily alcohol intake in selectively bred Sardinian alcohol-preferring (sP) (13) and alcohol-preferring UChB (3) rats; fully compensatory increases in daily water intake and lack of effect on spontaneous locomotor activity indicated that the reducing effect of baclofen on alcohol intake was not attributable to any baclofen-induced motor-incapacitating or sedative effect (that would otherwise disrupt the normal rates of drinking) (3, 13).
Although generally consistent in reporting a reducing effect of treatment with baclofen on alcohol drinking, studies conducted to date have reported considerable differences in baclofen efficacy. These differences are likely due to diversities in drinking history (resulting or not in the development of an addiction-like state) and genetic background of rats and mice used in those studies. An additional explanation of the differential efficacy of baclofen in reducing alcohol drinking has been proposed to reside in the at times reported opposite effect of R(+)- and S(-)-baclofen enantiomers on some alcohol-related behaviors [(18); see however (19)].
The suppressing effect of 5 mg/kg baclofen (i.p.) on alcohol intake in rats was fully prevented by pretreatment with the GABAB receptor antagonists, phaclofen and CGP36742 (20). These results provide strong evidence that baclofen effect on alcohol drinking is secondary to activation of the GABAB receptor.
Repeated treatment with baclofen (1–3 mg/kg, i.p.) over the initial phase of exposure to alcohol prevented acquisition of alcohol drinking in sP rats (21). These data suggest that activation of the GABAB receptor blocked detection of the psychopharmacological effects of alcohol underlying alcohol drinking. Rats acquired alcohol drinking behavior only once treatment with baclofen had been ceased (21). The translational value of these results may reside in pharmacologically delaying the onset of excessive alcohol drinking during adolescence and early adulthood, with the intent of potentially reducing the risk of developing AUD later in life.
Binge-Like Drinking
Baclofen has also been tested in two validated mouse models of binge drinking, named “drinking-in-the-dark” (DID) and “scheduled high alcohol consumption” (SHAC), respectively. The DID procedure is based on exposure of mice to alcohol in brief (2–4 h) daily drinking sessions occurring at fixed times during the early period of the dark phase of the daily light/dark cycle [(22); for review, see (23)]. In the SHAC procedure, water-deprived mice are given daily periods of fluid access varying between 4 and 10 h; every third day, an alcohol bottle is presented over the initial 30 min of the drinking session (24). Both procedures result in excessive alcohol drinking and intoxicating blood alcohol levels at the end of the drinking session, reproducing the “too much, too fast” condition of human binge drinking.
In the “DID” studies, systemic administration of doses of R(+)-baclofen in the 5–10 mg/kg range markedly reduced alcohol intake in C57BL/6J mice (18, 25), selectively bred High Alcohol Preferring 1 (HAP1) mice (18), and High DID (HDID) mice (selectively bred for high alcohol drinking under the DID regimen) (26). When tested in the SHAC procedure, baclofen (2.5 and 5 mg/kg, i.p.) dose-dependently reduced—up to complete suppression—alcohol intake in Withdrawal Seizure Control mice (27).
Relapse-Like Drinking
Relapse drinking is modeled in rodents by the so-called “alcohol deprivation effect” (ADE), that is the transient increase in voluntary alcohol intake occurring after a relatively long period of forced abstinence from alcohol [see (28)]. The effect of baclofen on ADE has been investigated in alcohol-preferring sP rats (29, 30) and alcohol-addicted Wistar rats (31).
In the two studies employing sP rats (29, 30), animals were initially exposed to a period of continuous alcohol drinking under the 2- or 4-bottle “alcohol vs. water” choice regimen (in the latter case, multiple alcohol concentrations were concurrently available), during which rats developed high and steady daily intakes of alcohol. Rats were then deprived of alcohol for 7–14 consecutive days. Re-exposure to alcohol resulted in a substantial increase in alcohol intake over the first hour of re-access as well as in a shift in preference for the highest concentrated alcohol solution. Acute treatment with baclofen (1–3 mg/kg, i.p.), administered immediately before re-exposure to alcohol, produced a complete blockade of both ADE-associated events (increase in alcohol intake and shift in alcohol preference). The lack of baclofen effect on food and water intake and spontaneous locomotor activity conferred specificity for alcohol intake to the reducing effect of baclofen (29, 30).
In the study employing Wistar rats (31), animals were exposed to long periods of alcohol drinking interposed with periods of alcohol abstinence, resulting—after ~1 year—in the development of addiction-like behaviors. Baclofen (1 and 3 mg/kg, i.p.) was injected repeatedly over the last drinking and deprivation phases. Treatment with 3, but not 1, mg/kg baclofen (i.p.) significantly reduced the post-abstinence, extra-intake of alcohol; specificity was not complete, as the reducing effect of baclofen on alcohol drinking was accompanied by a reduction in spontaneous locomotor activity, suggestive of a sedative effect. Again, drinking history and genetic background of rats may explain the differences observed in the ADE studies on baclofen.
Baclofen Effect on Operant Alcohol Self-Administration
A major step forward in the assessment of the preclinical, anti-alcohol profile of baclofen has been represented by the several studies using operant procedures of oral alcohol self-administration, in which alcohol is made available once the animal has activated an operandum (usually a lever or a nose-poke). Operant procedures allow measurement not only of the mere consumption of alcohol but also of the amount of “work” that the animal is willing to perform to access alcohol; when a high workload is required, operant procedures well model the human condition of excessive amounts of time spent in obtaining and using alcohol [a fundamental criterion for diagnosis of AUD (32)].
Rodent studies on baclofen have focused mainly on the use of two different procedures of oral alcohol self-administration: (i) fixed ratio (FR) schedule of reinforcement and (ii) progressive ratio (PR) schedule of reinforcement. Under the FR schedule, response requirement (RR; i.e., the “cost” of each alcohol presentation in terms of responses on the operandum) is predetermined and maintained throughout the session; this schedule provides a measure of alcohol consumption and reinforcing properties of alcohol [see (33)]. Under the PR schedule, RR is progressively increased after the delivery of each reinforcer; the lowest ratio not completed (breakpoint) provides a measure of motivational properties of alcohol [see (33)].
Rat studies have almost unequivocally reported the ability of systemic baclofen [0.5–5.6 mg/kg (i.p.) or corresponding doses of R(+)-baclofen] to markedly reduce alcohol self-administration under the FR schedule of reinforcement (with FR varying from FR1 to FR4); this effect was observed both in selectively bred alcohol-preferring rats (19, 34–36) and unselected Wistar and Long Evans rats (37–42). A mouse study reported similar results: treatment with baclofen (1–17 mg/kg, i.p.) reduced lever-responding for alcohol (43).
Interesting results, with possible translational value, have been yielded by “FR” studies testing baclofen in rats with high levels of responding for alcohol and large amounts of self-administered alcohol. Specifically, treatment with baclofen resulted to be particularly effective in Indiana alcohol-preferring (P) rats (36) and Wistar rats made physically dependent on alcohol by exposure to alcohol vapors (40). These data apparently mirror the results of clinical studies suggesting a greater efficacy of baclofen in patients affected by severe AUD [see (44)].
The relatively few studies using the PR schedule of reinforcement generated results similar to those of the “FR” studies: treatment with baclofen (1–3 mg/kg, i.p.) effectively reduced lever-responding and breakpoint for alcohol in different lines of selectively bred alcohol-preferring rats (36, 45) as well as in alcohol-dependent and –non-dependent Wistar rats (40).
The selectivity of the reducing effect of baclofen on alcohol self-administration was limited; treatment with baclofen reduced indeed self-administration of alternative, non-drug reinforcers—such as sucrose or saccharin solutions or regular food pellets—with potency and efficacy often comparable to those observed in “alcohol” experiments (34, 36, 38, 39, 45). Some studies also reported partial overlap between baclofen doses reducing alcohol self-administration and those inducing hypolocomotion (43), suggesting a possible confounding impact of baclofen-induced motor-incoordination on lever-responding for alcohol.
Operant procedures also allow the investigation of alcohol seeking, separated from any alcohol drinking. This may be done with animals trained to respond for alcohol and then exposed to test sessions during which responding are never reinforced: the only measurable outcome is extinction responding (ER). ER is taken as measure of the appetitive and motivational properties of alcohol [see (33)]. An alternative experimental procedure (commonly named “sipper”) – that provides a clear separation between the appetitive and consummatory phases of alcohol self-administration within a single session—is based on animals trained to complete a single RR (usually, 16–30 lever-responses) to gain access to alcohol for a substantial period of time (usually, 20 min) [see (46)]. In an “ER” study (47), treatment with 1–3 mg/kg baclofen (i.p.) completely suppressed ER for alcohol in alcohol-preferring sP rats; although not influenced by any motor-incoordinating effect, the suppressing effect of baclofen on ER was not selective for alcohol, as baclofen treatment also suppressed ER for a sucrose solution. A subsequent “ER” study using Long Evans rats reported a comparable reduction of ER for alcohol and sucrose after treatment with 3 mg/kg baclofen (i.p.) (48). When tested under the “sipper” procedure, systemic administration of baclofen reduced lever-responding to access alcohol in Long Evans rats (48) and C576BL/6 mice (27); in both studies, treatment with baclofen also affected lever-responding for sucrose, limiting the selectivity of baclofen effect.
Two recent studies (49, 50) investigated the effect of baclofen on alcohol self-administration in non-human primates. In both studies, adult male baboons were exposed to a chained schedule of reinforcement with three linked components; sequential completion of RR of each component made alcohol available. Baclofen was injected intramuscularly at doses varying between 0.1 and 2.4 mg/kg. Treatment with baclofen decreased lever-responding for alcohol, number of alcohol drinks, and amount of self-administered alcohol. Treatment with baclofen was effective when initiated during ongoing alcohol access, but not when initiated during an alcohol-abstinence period preceding alcohol access (50). These data are in agreement with the results of human studies indicating a greater efficacy of baclofen when treatment was initiated during active drinking [e.g., (51)] rather than after abstinence had been achieved [e.g., (52)]. An additional experiment found that baclofen treatment facilitated ER for alcohol (49). As in the majority of rodent studies of alcohol self-administration, in these two monkey studies selectivity of baclofen effect was modest, as baclofen also reduced self-administration of a non-drug reinforcer (orange-flavored beverage). Sedation and transient side-effects were also observed.
Baclofen Effect on Reinstatement of Alcohol Seeking
Two rodent studies investigated the effect of baclofen on reinstatement of alcohol-seeking behavior. In this procedure, largely used in the alcohol and drug addiction field, previously extinguished unreinforced lever-responding or nose-poking for alcohol is reinstated by (i) environmental stimuli previously associated to alcohol availability, (ii) limited availability of alcohol, (iii) exposure to stressors, or (iv) administration of specific drugs (e.g., nicotine and cannabinoids). Reinstatement of alcohol-seeking behavior models loss of control over alcohol and relapse episodes in AUD patients [see (28)], resulting to be complementary to ADE.
In the first study (53), alcohol-preferring sP rats—trained to lever-respond for alcohol under the FR4 schedule of reinforcement—were exposed to a single session made of an initial phase of ER followed, once lever-responding for alcohol was virtually completely extinguished, by a reinstatement phase; the latter was preceded by an alcohol-associated stimulus complex, that effectively reinstated lever-responding (still unreinforced). Acute treatment with baclofen (3 mg/kg, i.p.), given after extinction of lever-responding and 30 min before presentation of the alcohol-associated stimulus complex, resulted in a marked reduction of an otherwise robust reinstatement of lever-responding. These data complement well with those reporting the ability of 1–3 mg/kg baclofen in suppressing relapse-like drinking in sP rats exposed to the ADE procedure (29, 30).
In the second study (31), Wistar rats—trained to nose-poke for alcohol under the FR3 schedule of reinforcement—were first exposed to a series of ER sessions and then to reinstatement sessions in which unreinforced nose-poking was reinstated by the presentation of alcohol-associated stimuli. Treatment with baclofen (1 and 3 mg/kg, i.p.) fully abolished, in a dose-related manner, reinstatement of nose-poking.
Mechanism of Action of Baclofen Effects on Alcohol-Related Behaviors
Several lines of experimental evidence converge to support the hypothesis that the suppressing effect of baclofen on multiple alcohol-related behaviors are mediated by the activation of GABAB receptors located in the ventral tegmental area (VTA), a key area of the mesolimbic dopamine system [i.e., the neuronal system mediating the rewarding, reinforcing, motivational, and stimulating properties of natural stimuli and drugs of abuse [see (54)], including alcohol [see (55)]. Indeed, baclofen microinjection into the VTA of rats and mice suppressed several alcohol-motivated behaviors and in vivo actions of alcohol, including (a) alcohol drinking (56), (b) alcohol self-administration (57), (c) alcohol seeking (58), (d) alcohol-stimulated locomotor activity (8, 59), (e) alcohol-induced sensitization of locomotor activity (59), and (f) alcohol-induced conditioned place preference (60). More specifically, intra-VTA microinjection of 0.03–0.3 μg baclofen dose-dependently suppressed lever-responding for alcohol in sP rats (57); suppression of lever-responding for alcohol was particularly evident over the first minutes of the test session, suggestive of the ability of intra-VTA baclofen to suppress rat motivation to start seeking and consuming alcohol. The effect of intra-VTA baclofen on alcohol self-administration was site-specific and devoid of any motor-incoordinating effect (57).
In close agreement with the above data, and as further confirmation of the hypothesis relating to the hyperpolarization of mesolimbic dopamine neurons as the mechanism of action through which baclofen suppresses alcohol-related behaviors, intra-VTA microinjection of baclofen suppressed dopamine release—stimulated by cues anticipating alcohol reinforcement—in the rat nucleus accumbens (NAc; the target brain area of mesolimbic dopamine neurons) (58, 61, 62).
Brain regions other than VTA likely contribute to mediation of the suppressing effects of baclofen on alcohol-related behaviors. Accordingly, recent experimental data highlighted a role for the ventral pallidum (VP), a brain area to which GABAergic neurons located in the NAc project their axons; indeed, baclofen microinjection into the VP reduced alcohol intake in selectively bred alcohol-preferring Alko Alcohol (AA) rats (63). More recent data pointed to involvement of the amygdala: due to reduced levels of the GABA transporter GAT3, high concentrations of extracellular GABA have been found in the amygdala of alcohol-dependent rats (64). It has been proposed that baclofen-induced activation of amygdalar presynaptic GABAB receptor would lower extracellular GABA, possibly normalizing the enhanced tonic inhibition of amygdala and, subsequently, reducing excessive alcohol drinking (65).
Baclofen Effect on Alcohol Withdrawal Syndrome
An additional series of in vivo studies tested the ability of baclofen to ameliorate signs of alcohol withdrawal syndrome (AWS) in rats. AWS is experimentally induced by the abrupt termination of alcohol administration to rats made physically dependent on alcohol by the forced, prolonged exposure to intoxicating amounts of alcohol [e.g., (66)]. The resulting signs closely resemble those observed in AUD patients (67, 68).
Treatment with baclofen (1.25–25 mg/kg, i.p.) suppressed several AWS signs, including increase in alcohol self-administration, anxiety-related behaviors, tremors, and seizures in alcohol-dependent Wistar, Sprague-Dawley, and Lister rats (13, 40, 69, 70). The ability of baclofen to effectively suppress AWS signs in rats has since been effectively translated to AUD patients [e.g., (71)]. A GABAB receptor-mediated counterbalance of the AWS-associated, enhanced function of glutamate excitatory neurotransmission has been proposed as the mechanism by means of which baclofen exerts its suppressing effects on AWS signs (13, 40).
Conclusions
Treatment with the prototypic, orthosteric agonist of the GABAB receptor, baclofen, suppressed several different alcohol-related behaviors in laboratory rodents and non-human primates. These results are of relevance as they suggest a critical role for the GABAB receptor in the neural substrate underlying alcohol seeking and drinking. Additionally, these data possess remarkable translational value, as most of the effects of baclofen observed in animals have subsequently been reproduced in AUD patients: most of the clinical surveys conducted to date indeed reported substantial reductions in alcohol drinking and craving for alcohol after treatment with baclofen [see (62, 72)], making baclofen a promising pharmacotherapy for AUD.
The limited separation between baclofen-induced “desired” pharmacological effects and “unwanted” sedative effects appears to be the most relevant drawback of the anti-alcohol profile of baclofen. A major step forward in this field is likely represented by the positive allosteric modulators (PAMs) of the GABAB receptor; notably, rodent data collected to date on this new class of GABAB receptor ligands suggest indeed that GABAB PAMs reproduce all the anti-addictive properties of baclofen at doses largely lower than those inducing motor-incoordination and sedation [see (62, 73–75)]. Since the first GABAB PAMs are now approaching clinical testing, it will soon be possible to assess whether they retain baclofen effects, while possessing higher therapeutic index and more favorable side-effect profile, also in humans.
Author Contributions
GC and GG contributed equally to literature search and manuscript writing. Both authors approved the final draft of the manuscript.
Funding
The present study was supported by funds from the National Research Council of Italy to GC.
Conflict of Interest Statement
GC and GG are inventors of a European patent on “The use of baclofen in the treatment of alcoholism”. GC is partner of Cagliari Pharmacological Research (Cagliari, Italy), owner of the above patent.
Acknowledgments
The authors are grateful to Ms. Anne Farmer for language editing of the manuscript.
References
1. Cott J, Carlsson A, Engel J, Lindqvist M. Suppression of ethanol-induced locomotor stimulation by GABA-like drugs. Naunyn Schmiedebergs Arch Pharmacol. (1976) 295:203–9. doi: 10.1007/BF00505087
2. Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev. (1987) 94:469–92. doi: 10.1037/0033-295X.94.4.469
3. Quintanilla ME, Perez E, Tampier L. Baclofen reduces ethanol intake in high-alcohol-drinking University of Chile bibulous rats. Addict Biol. (2008) 13:326–36. doi: 10.1111/j.1369-1600.2008.00102.x
4. Humeniuk RE, White JM, Ong J. The role of GABAB receptors in mediating the stimulatory effects of ethanol in mice. Psychopharmacology (1993) 111:219–24. doi: 10.1007/BF02245527
5. Shen EH, Dorow J, Harland R, Burkhart-Kasch S, Phillips TJ. Seizure sensitivity and GABAergic modulation of ethanol sensitivity in selectively bred FAST and SLOW mouse lines. J Pharmacol Exp Ther. (1998) 287:606–15.
6. Broadbent J, Harless WE. Differential effects of GABAA and GABAB agonists on sensitization to the locomotor stimulant effects of ethanol in DBA/2 J mice. Psychopharmacology (1999) 141:197–205. doi: 10.1007/s002130050825
7. Chester JA, Cunningham CL. Baclofen alters ethanol-stimulated activity but not conditioned place preference or taste aversion in mice. Pharmacol Biochem Behav. (1999) 63:325–31. doi: 10.1016/S0091-3057(98)00253-6
8. Boehm SL, Piercy MM, Bergstrom HC, Phillips TJ. Ventral tegmental area region governs GABAB receptor modulation of ethanol-stimulated activity in mice. Neuroscience (2002) 115:185–200. doi: 10.1016/S0306-4522(02)00378-0
9. Holstein SE, Dobbs L, Phillips TJ. Attenuation of the stimulant response to ethanol is associated with enhanced ataxia for a GABAA, but not a GABAB, receptor agonist. Alcohol Clin Exp Res. (2009) 33:108–20. doi: 10.1111/j.1530-0277.2008.00817.x
10. Arias C, Mlewski EC, Molina JC, Spear NE. Naloxone and baclofen attenuate ethanol's locomotor-activating effects in preweanling Sprague-Dawley rats. Behav Neurosci. (2009) 123:172–80. doi: 10.1037/a0014049
11. Bell RL, Hauser SR, Liang T, Sari Y, Maldonado-Devincci A, Rodd ZA. Rat animal models for screening medications to treat alcohol use disorders. Neuropharmacology (2017) 122:201–43. doi: 10.1016/j.neuropharm.2017.02.004
12. Daoust M, Saligaut C, Lhuintre JP, Moore N, Flipo JL, Boismare F. GABA transmission, but not benzodiazepine receptor stimulation, modulates ethanol intake by rats. Alcohol (1987) 4:469–72. doi: 10.1016/0741-8329(87)90087-5
13. Colombo G, Agabio R, Carai MAM, Lobina C, Pani M, Reali R, et al. Ability of baclofen in reducing alcohol intake and withdrawal severity: I – Preclinical evidence. Alcohol Clin Exp Res. (2000) 24:58–66. doi: 10.1111/j.1530-0277.2000.tb04554.x
14. Stromberg MF. The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat. Pharmacol Biochem Behav. (2004) 78:743–50. doi: 10.1016/j.pbb.2004.05.006
15. Peters S, Slattery DA, Flor PJ, Neumann ID, Reber SO. Differential effects of baclofen and oxytocin on the increased ethanol consumption following chronic psychosocial stress in mice. Addict Biol. (2013) 18:66–77. doi: 10.1111/adb.12001
16. Villas Boas GR, Zamboni CG, Peretti MC, Correia D, Rueda AV, Camarini R, et al. GABAB receptor agonist only reduces ethanol drinking in light-drinking mice. Pharmacol Biochem Behav. (2012) 102:233–40. doi: 10.1016/j.pbb.2012.04.011
17. Smith BR, Boyle AEL, Amit Z. The effects of GABAB agonist baclofen on the temporal and structural characteristics of ethanol intake. Alcohol (1999) 17:231–40. doi: 10.1016/S0741-8329(98)00053-6
18. Kasten CR, Blasingame SN, Boehm SL. Bidirectional enantioselective effects of the GABAB receptor agonist baclofen in two mouse models of excessive ethanol consumption. Alcohol (2015) 49:37–46. doi: 10.1016/j.alcohol.2014.11.005
19. Lorrai I, Maccioni P, Gessa GL, Colombo G. R(+)-baclofen, but not S(-)-baclofen, alters alcohol self-administration in alcohol-preferring rats. Front Psychiatr. (2016) 7:68. doi: 10.3389/fpsyt.2016.00068
20. Perfumi M, Santoni M, Ciccocioppo R, Massi M. Blockade of gamma-aminobutyric acid receptors does not modify the inhibiton of ethanol intake induced by Hypericum perforatum in rats. Alcohol Alcohol (2002) 37:540–6. doi: 10.1093/alcalc/37.6.540
21. Colombo G, Serra S, Brunetti G, Atzori G, Pani M, Vacca G, et al. The GABAB receptor agonists baclofen and CGP 44532 prevent acquisition of alcohol drinking behaviour in alcohol-preferring rats. Alcohol Alcohol. (2002) 37:499–503. doi: 10.1093/alcalc/37.5.499
22. Rhodes JS, Best K, Belknap JK, Finn DA, Crabbe JC. Evaluation of a simple model of ethanol drinking to intoxication in C57BL/6J mice. Physiol Behav. (2005) 84:53–63. doi: 10.1016/j.physbeh.2004.10.007
23. Thiele TE, Navarro M. “Drinking in the dark” (DID) procedures: a model of binge-like ethanol drinking in non-dependent mice. Alcohol (2014) 48:235–41. doi: 10.1016/j.alcohol.2013.08.005
24. Finn DA, Belknap JK, Cronise K, Yoneyama N, Murillo A, Crabbe JC. A procedure to produce high alcohol intake in mice. Psychopharmacology (2005) 178:471–80. doi: 10.1007/s00213-004-2039-8
25. Kasten CR, Frazee AM, Boehm SL. Developing a model of limited-access nicotine consumption in C57Bl/6J mice. Pharmacol Biochem Behav. (2016) 148:28–37. doi: 10.1016/j.pbb.2016.05.010
26. Crabbe JC, Ozburn AR, Metten P, Barkley-Levenson A, Schlumbohm JP, Spence SE, et al. High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking. Pharmacol Biochem Behav. (2017) 160:55–62. doi: 10.1016/j.pbb.2017.08.002
27. Tanchuck MA, Yoneyama N, Ford MM, Fretwell AM, Finn DA. Assessment of GABA-B, metabotropic glutamate, and opioid receptor involvement in an animal model of binge drinking. Alcohol (2010) 45:33–44. doi: 10.1016/j.alcohol.2010.07.009
28. Martin-Fardon R, Weiss F. Modeling relapse in animals. Curr Top Behav Neurosci. (2013) 13:403–32. doi: 10.1007/978-3-642-28720-6_202
29. Colombo G, Serra S, Brunetti G, Vacca G, Carai MAM, Gessa GL. Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend (2003) 70:105–8. doi: 10.1016/S0376-8716(02)00333-2
30. Colombo G, Serra S, Vacca G, Carai MAM, Gessa GL. Baclofen-induced suppression of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats exposed to different alcohol concentrations. Eur J Pharmacol. (2006) 550:123–6. doi: 10.1016/j.ejphar.2006.08.052
31. Vengeliene V, Takahashi TT, Dravolina OA, Belozertseva I, Zvartau E, Bespalov AY, et al. Efficacy and side effects of baclofen and the novel GABAB receptor positive allosteric modulator CMPPE in animal models for alcohol and cocaine addiction. Psychopharmacology (2018) 235:1955–65. doi: 10.1007/s00213-018-4893-9
32. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Association (2013).
33. Markou A, Weiss F, Gold LH, Caine SB, Schulteis G, Koob GF. Animal models of drug craving. Psychopharmacology (1993) 112:163–82. doi: 10.1007/BF02244907
34. Maccioni P, Serra S, Vacca G, Orrù A, Pes D, Agabio R, et al. Baclofen-induced reduction of alcohol reinforcement in alcohol-preferring rats. Alcohol (2005) 36:161–8. doi: 10.1016/j.alcohol.2005.08.003
35. Liang JH, Chen F, Krstew E, Cowen MS, Carroll FY, Crawford D, et al. The GABAB receptor allosteric modulator CGP7930, like baclofen, reduces operant self-administration of ethanol in alcohol-preferring rats. Neuropharmacology (2006) 50:632–9. doi: 10.1016/j.neuropharm.2005.11.011
36. Maccioni P, Zaru A, Loi B, Lobina C, Carai MAM, Gessa GL, et al. Comparison of the effect of the GABAB receptor agonist, baclofen, and the positive allosteric modulator of the GABAB receptor, GS39783, on alcohol self-administration in three different lines of alcohol-preferring rats. Alcohol Clin Exp Res. (2012) 36:1748–66. doi: 10.1111/j.1530-0277.2012.01782.x
37. Petry NM. Benzodiazepine-GABA modulation of concurrent ethanol and sucrose reinforcement in the rat. Exp Clin Psychopharmacol. (1997) 5:183–94. doi: 10.1037/1064-1297.5.3.183
38. Anstrom KK, Cromwell HC, Markowski T, Woodward DJ. Effect of baclofen on alcohol and sucrose self-administration in rats. Alcohol Clin Exp Res. (2003) 27:900–8. doi: 10.1111/j.1530-0277.2003.tb04414.x
39. Janak PH, Gill TM. Comparison of the effects of allopregnanolone with direct GABAergic agonists on ethanol self-administration with and without concurrently available sucrose. Alcohol (2003) 30:1–7. doi: 10.1016/S0741-8329(03)00068-5
40. Walker BM, Koob GF. The γ-aminobutyric acid-B receptor agonist baclofen attenuates responding for ethanol in ethanol-dependent rats. Alcohol Clin Exp Res. (2007) 31:11–8. doi: 10.1111/j.1530-0277.2006.00259.x
41. Dean RL, Eyerman D, Todtenkopf MS, Turncliff RZ, Bidlack JM, Deaver DR. Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats. Pharmacol Biochem Behav. (2011) 100:530–7. doi: 10.1016/j.pbb.2011.10.019
42. Williams KL, Nickel MM, Bielak JT. Baclofen blocks yohimbine-induced increases in ethanol-reinforced responding in rats. Pharmacol Biochem Behav. (2016) 144:20–5. doi: 10.1016/j.pbb.2016.02.010
43. Besheer J, Lepoutre V, Hodge CW. GABAB receptor agonists reduce operant ethanol self-administration and enhance ethanol sedation in C57BL/6J mice. Psychopharmacology (2004) 74:358–66. doi: 10.1007/s00213-003-1769-3
44. Leggio L, Garbutt JC, Addolorato G. Effectiveness and safety of baclofen in the treatment of alcohol dependent patients. CNS Neurol Disord Drug Targets (2010) 9:33–44. doi: 10.2174/187152710790966614
45. Maccioni P, Fantini N, Froestl W, Carai MAM, Gessa GL, Colombo G. Specific reduction of alcohol's motivational properties by the positive allosteric modulator of the GABAB receptor, GS39783 – comparison with the effect of the GABAB receptor direct agonist, baclofen. Alcohol Clin Exp Res. (2008) 32:1558–64. doi: 10.1111/j.1530-0277.2008.00725.x
46. Samson HH, Slawecki CJ, Sharpe AL, Chappell A. Appetitive and consummatory behaviors in the control of ethanol consumption: a measure of ethanol seeking behavior. Alcohol Clin Exp Res. (1998) 22:1783–7.
47. Colombo G, Vacca G, Serra S, Brunetti G, Carai MAM, Gessa GL. Baclofen suppresses motivation to consume alcohol in rats. Psychopharmacology (2003) 167:221–4. doi: 10.1007/s00213-003-1397-y
48. Czachowski CL, Legg BH, Stansfield KH. Ethanol and sucrose seeking and consumption following repeated administration of the GABAB agonist baclofen in rats. Alcohol Clin Exp Res. (2006) 30:812–8. doi: 10.1111/j.1530-0277.2006.00094.x
49. Duke AN, Kaminski BJ, Weerts EM. Baclofen effects on alcohol seeking, self-administration and extinction of seeking responses in a within-session design in baboons. Addict Biol. (2014) 19:16–26. doi: 10.1111/j.1369-1600.2012.00448.x
50. Holtyn AF, Kaminski BJ, Weerts EM. Baclofen and naltrexone effects on alcohol self-administration: comparison of treatment initiated during abstinence or ongoing alcohol access in baboons. Drug Alcohol Depend (2017) 179:47–54. doi: 10.1016/j.drugalcdep.2017.06.019
51. Addolorato G, Leggio L, Ferrulli A, Cardone S, Vonghia L, Mirijello A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet (2007) 370:1915–22. doi: 10.1016/S0140-6736(07)61814-5
52. Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA. Efficacy and safety of baclofen for alcohol dependence: A randomized, double-blind, placebo-controlled trial. Alcohol Clin Exp Res. (2010) 34:1849–57. doi: 10.1111/j.1530-0277.2010.01273.x
53. Maccioni P, Bienkowski P, Carai MAM, Gessa GL, Colombo G. Baclofen attenuates cue-induced reinstatement of alcohol-seeking behavior in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend (2008) 95:284–7. doi: 10.1016/j.drugalcdep.2008.02.006
54. Volkow ND, Wise RA, Baler R. The dopamine motive system: implications for drug and food addiction. Nat Rev Neurosci. (2017) 18:741–52. doi: 10.1038/nrn.2017.130
55. Tabakoff B, Hoffman PL. The neurobiology of alcohol consumption and alcoholism: an integrative history. Pharmacol Biochem Behav. (2013) 113:20–37. doi: 10.1016/j.pbb.2013.10.009
56. Moore EM, Boehm SL. Site-specific microinjection of baclofen into the anterior ventral tegmental area reduces binge-like ethanol intake in male C57BL/6J mice. Behav Neurosci. (2009) 123:555–63. doi: 10.1037/a0015345
57. Maccioni P, Lorrai I, Contini A, Leite-Morris K, Colombo G. Microinjection of baclofen and CGP7930 into the ventral tegmental area suppresses alcohol self-administration in alcohol-preferring rats. Neuropharmacology (2018) 136:146–58. doi: 10.1016/j.neuropharm.2017.10.012
58. Leite-Morris KA, Misch ES, Czachowski CL. Intra-VTA activation of GABA(B) receptors modulates accumbal dopamine during ethanol seeking behavior. Alcohol Clin Exp Res. (2008) 32:276A.
59. Leite-Morris KA. The effects of ventral tegmental baclofen on ethanol-induced motor stimulation and sensitization in DBA/2 mice. Alcohol Clin Exp Res. (2004) 28:182A.
60. Bechtholt AJ, Cunningham CL. Ethanol-induced conditioned place preference is expressed through a ventral tegmental area dependent mechanism. Behav Neurosci. (2005) 119:213–23. doi: 10.1037/0735-7044.119.1.213
61. Leite-Morris KA. Neurochemistry and neuropharmacology of the GABA-B receptor in a rodent model of alcohol binge drinking. Alcohol Clin Exp Res. (2013) 37:255A.
62. Agabio R, Leite-Morris K, Addolorato G, Colombo G. Targeting the GABAB receptor for the treatment of alcohol use disorder. In: Colombo G, editor. GABAB Receptor; The Receptors 29. Cham: Springer International Publishing (2016). 287–307.
63. Kemppainen H, Raivio N, Kiianmaa K. Role for ventral pallidal GABAergic mechanisms in the regulation of ethanol self-administration. Psychopharmacology (2012) 223:211–21. doi: 10.1007/s00213-012-2709-x
64. Augier E, Barbier E, Dulman RS, Licheri V, Augier G, Domi E, et al. A molecular mechanism for choosing alcohol over an alternative reward. Science (2018) 360:1321–6. doi: 10.1126/science.aao1157
65. Spanagel R. Aberrant choice behavior in alcoholism. Science (2018) 360:1298–9. doi: 10.1126/science.aau0668
66. Majchrowicz E. Induction of physical dependence upon ethanol and the associated behavioral changes in rats. Psychopharmacologia (1975) 43:245–54. doi: 10.1007/BF00429258
67. Majchrowicz E. Comparison of ethanol withdrawal syndrome in humans and rats. Adv Exp Med Biol. (1977) 55B:15–23.
68. Becker HC. Animal models of alcohol withdrawal. Alcohol Res Health (2000) 24:105–13. doi: 10.2307/4066289
69. File SE, Zharkovsky A, Gulati K. Effects of baclofen and nitrendipine on ethanol withdrawal responses in the rat. Neuropharmacology (1991) 30:183–90.
70. Knapp DJ, Overstreet DH, Breese GR. Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal. Alcohol Clin Exp Res. (2007) 31:582–95. doi: 10.1111/j.1530-0277.2007.00342.x
71. Addolorato G, Leggio L, Abenavoli L, Agabio R, Caputo F, Capristo E, et al, Gasbarrini. Baclofen in the treatment of alcohol withdrawal syndrome: a randomized comparative study versus diazepam. Am J Med. (2006) 119:276.e13–8. doi: 10.1016/j.amjmed.2005.08.042
72. Mirijello A, Caputo F, Vassallo G, Rolland B, Tarli C, Gasbarrini A, Addolorato G. GABAB agonists for the treatment of alcohol use disorder. Curr Pharm Des. (2015) 21:3367–72. doi: 10.2174/1381612821666150619091858
73. Felice D, O'Leary OF, Cryan JF. Targeting the GABAB receptor for the treatment of psychiatric disorders. In: Colombo G, editor. GABAB Receptor; The Receptors 29. Cham: Springer International Publishing (2016). p. 219–50.
74. Frankowska M, Przegalinski E, Filip M. Targeting the GABAB receptor for the treatment of substance use disorder. In: Colombo G, editor. GABAB Receptor; The Receptors 29. Cham: Springer International Publishing (2016). 263–86.
Keywords: baclofen, GABAB receptor, alcohol drinking and seeking, reinstatement of alcohol seeking, animal models of alcohol use disorder
Citation: Colombo G and Gessa GL (2018) Suppressing Effect of Baclofen on Multiple Alcohol-Related Behaviors in Laboratory Animals. Front. Psychiatry 9:475. doi: 10.3389/fpsyt.2018.00475
Received: 16 May 2018; Accepted: 10 September 2018;
Published: 28 September 2018.
Edited by:
Mathis Heydtmann, NHS Greater Glasgow and Clyde, United KingdomReviewed by:
Carla Cannizzaro, Università degli Studi di Palermo, ItalyPhilippe Rondard, Centre National de la Recherche Scientifique (CNRS), France
Copyright © 2018 Colombo and Gessa. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Giancarlo Colombo, colomb@unica.it